** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.61% to $39.11 premarket
** Co sees Q2 revenue to be between $530 million and $550 million, below estimates of $564.6 million - data compiled by LSEG
** HIMS expects onetime quarter-over-quarter revenue drop in Q2, as it transitions subscribers previously on commercially available dosages of Novo Nordisk's NOVOb.CO semaglutide to options on its or other platforms by end of quarter
** Reaffirms full-year revenue forecast of $2.3 billion to $2.4 billion
** We suspect that the re-affirmed 2025 and new Q2 forecast is likely "conservative," brokerage BTIG says
** Q1 revenue of $586.0 million beats estimates of $538.2 million
** Up to last close, stock up ~73% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.